BriaCell Therapeutics Corp., announced that its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
[BriaCell Therapeutics Corp.]
Sorry, but the selected Zotpress account can't be found.
